Arixtra is obtained by chemical synthesis. It is an injectable anticoagulant that selectively inhibits FXa. In low doses it is used in the preventive treatment of venous thromboembolic accidents and in high doses it is used in the treatment of venous thrombosis.
Special plasmas are derived from patients with a congenital deficiency, severe or moderate, or presenting a particular profile. No buffer or preservatives are added. Quickly frozen at -80° C, the plasma maintains perfectly intact the matrix. All plasmas are stable when stored at -40° C to -80° C. We carefully pack with dry ice during shipment. No additive or preservative. Expiry date > 1 year. Plastic vials.
Minimize test time. Ready to use.